Psychopharmacology and Psychiatry Updates

265 Episodo

1. Association Between Mood Disorders and COVID-19

   Publicado: 16/6/2022
2. Antidepressants and Naltrexone for Stimulant Use Disorder

   Publicado: 11/6/2022
3. CANMAT Task Force Recommendations for the Use of Ketamine

   Publicado: 6/6/2022
4. Stimulant Replacement Therapies for Methamphetamine and Amphetamine Use Disorder

   Publicado: 1/6/2022
5. Premenstrual Mood Syndromes

   Publicado: 27/5/2022
6. Stimulant Use Disorder: Diagnosis and Assessment

   Publicado: 22/5/2022
7. Zuranolone for Postpartum Depression

   Publicado: 17/5/2022
8. Long-Term Treatment of First Episode of Psychosis

   Publicado: 12/5/2022
9. The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia

   Publicado: 7/5/2022
10. Health Issues in First Episode of Psychosis

    Publicado: 2/5/2022
11. Psychopharmacology for Treatment-Resistant Early Psychosis

    Publicado: 27/4/2022
12. Assessing and Treating Adult ADHD

    Publicado: 22/4/2022
13. Medications for Binge Eating Disorder

    Publicado: 17/4/2022
14. Antipsychotics for First Episodes of Psychosis

    Publicado: 12/4/2022
15. Effects on Suicidal Risk With Different Medications

    Publicado: 7/4/2022
16. Risks of Using Cannabinoids

    Publicado: 2/4/2022
17. Lithium: How to Manage Dosage

    Publicado: 28/3/2022
18. CBD as a Medication

    Publicado: 23/3/2022
19. SSRIs and Suicidality

    Publicado: 18/3/2022
20. Cannabis and Cognition

    Publicado: 13/3/2022